\DUXARIL

 

Content  Almitrine bismesylate 30 mg, Raubasine 10 mg.
Description  Each tablet contains almitrine 30 mg and raubasine 10 mg. It also
contains the following excipients: Cornstarch, ethylcellulose, glycerin,
hydroxypropyl methylcellulose, lactose, CI natural red 4, titanium dioxide,
polyethylene glycol, povidone, colloidal silicon dioxide, magnesium stearate
and talc.
Actions  Antihypoxic drug.
Pharmacology: The actions of almitrine-raubasine have been demonstrated in
animals, in numerous models of experimental cerebral hypoxia, as well as in
man, in whom pharmacoclinical studies have demonstrated the following:
Increase in the arterial partial pressure of oxygen (PaO2);
Increase in the arterial saturation of oxygen (SaO2);
Decrease in the arterial desaturation during effort, a dynamic control
considered as one of the best techniques currently available to assess the
efficacy of an antihypoxic molecule;

Increase of the blood level of 2,3-diphosphoglycerate, a factor of oxygen
availability in the arterial blood;

Increase in the metabolism of the cerebral tissue as demonstrated, during the
glucose test, by the analysis of the cortical activity.

The improvement in the blood gas parameters under almitrine-raubasine is linked
to an improvement of the efficacy of the alveolar capillary exchange mechanism
without modification of the ventilatory parameters.

These properties explain the activity of almitrine-raubasine on the
psychobehavioural disturbances in the elderly.

Pharmacokinetics: Almitrine is rapidly absorbed and the plasmatic peak is
obtained within 3 hrs after oral administration. Almitrine and its metabolites
are mainly excreted through the biliary tract. The elimination is, thus, mainly
through the faeces. After single administration, the half-life is between 40-80
hrs; it is 30 days after repeated administration. The binding to protein is
high (>99%).

Raubasine is rapidly absorbed, and the plasmatic peak is obtained 1-2 hrs after
oral administration. After single administration, the half-life is between 7-15
hrs; it is 11 hrs after repeated administration.

Indication   Pathological loss of cognitive function related to cerebral aging.
Chorioretinal disorders of ischemic origin. Cochleovestibular disorders of
ischemic origin. Early & late sequelae of CVA.
Dosage   2 tab daily in 2 divided doses.
Contraindication   Avoid concurrent administration w/ MAOIs, almitrine.
Special Precaution   Pregnancy. Occurrence of neurological symptoms (prickling,
formication, numbness) should lead to w/drawal. The treatment does not
eliminate the need for specific treatment of hypertension.
Adverse Reaction   Have been occasionally reported during long-term treatment:
wt loss, peripheral neuropathy should lead to treatment w/drawal. Mild GI
disorders, sleep disturbances, drowsiness, agitation, anxiety, palpitation,
dizziness.
Side Effects  
Drug Interaction   MAOIs, other almitrine-containing prep.

Murray Grossan, M.D.
http://www.ent-consult.com

Besides the side effect, can the drug duxaril relieve you otitinus while
you taking on it .
kow

Besides the side effect, can the drug duxaril relieve you otitinus while
you taking on it .
kow